Compounded Semaglutide vs Brand Name Wegovy: Is It Worth the Savings?

If you’ve been prescribed semaglutide for weight loss — or you’re just looking into your options — you’ve probably run into a jarring reality: Wegovy, the brand-name version, can cost $1,300 to $1,500 per month out of pocket. For most people, that’s simply not sustainable.

Enter compounded semaglutide. Compounded versions have been widely available over the past couple of years, often priced at $150 to $400 per month — a fraction of the brand-name cost. But is compounded semaglutide actually safe? Is it effective? And is it still even available now that supply shortages are easing?

This guide breaks it all down in plain English. Always consult your doctor before starting or switching any medication.

What Is Compounded Semaglutide — and How Is It Different from Wegovy?

Wegovy is the FDA-approved brand-name injectable semaglutide made by Novo Nordisk. It’s been through rigorous clinical trials, has a standardized formulation, and comes in pre-filled auto-inject pens in set doses (0.25 mg up to 2.4 mg weekly).

Compounded semaglutide is made by licensed compounding pharmacies using the same active ingredient — semaglutide — but it’s mixed, prepared, and dispensed independently. Instead of a pre-filled pen from Novo Nordisk, you typically receive a multi-dose vial and syringes, and you draw and inject the dose yourself.

The key distinction: compounded semaglutide is not FDA-approved. That doesn’t mean it’s illegal — compounding itself is a well-established, legal pharmacy practice — but it does mean the specific compounded product hasn’t gone through the same approval process that Wegovy has.

Other differences worth knowing:

• Form factor: Wegovy uses a pre-filled pen; compounded versions typically use vials + syringes
• Additives: Some compounded formulas include B12 or other additives — these are not in Wegovy
• Dosing flexibility: Compounding pharmacies can customize doses more freely
• Salt form: Wegovy uses semaglutide free base; some compounders have used semaglutide sodium or acetate salts — the FDA has flagged concerns about this distinction

The Cost Reality: $1,400/Month vs. $250/Month

Let’s be blunt about the numbers:

• Wegovy (brand name): $1,300–$1,500/month without insurance; many insurance plans still don’t cover it for weight loss
• Ozempic (off-label for weight loss): Slightly cheaper than Wegovy but still $900–$1,100/month without coverage
• Compounded semaglutide: $150–$400/month depending on the pharmacy and dose

Novo Nordisk does offer a savings card that can reduce cost to around $650/month for commercially insured patients — but that still requires qualifying insurance and isn’t available on Medicare or Medicaid.

For people paying out of pocket, compounded semaglutide has made GLP-1 treatment accessible where it otherwise wouldn’t be. That’s not a small thing. Cost is a real barrier to healthcare.

How Compounding Pharmacies Work

Compounding pharmacies operate under state pharmacy boards and, for sterile injectables like semaglutide, must register with the FDA under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Here’s what that actually means in practice:

• 503A pharmacies compound medications for individual patients based on a valid prescription. They’re regulated at the state level with some federal oversight.
• 503B outsourcing facilities are federally registered, subject to FDA inspections, and held to Current Good Manufacturing Practice (CGMP) standards — much closer to pharmaceutical manufacturing standards.

The critical point: compounded drugs are not FDA-approved — meaning the FDA hasn’t evaluated the specific compound for safety, efficacy, or manufacturing quality. But legitimate, registered compounders operate under real regulatory oversight. It’s not a free-for-all.

The risk enters when people source semaglutide from unregulated online sellers, “peptide” suppliers, or gray-market sources. Those products have zero oversight and carry genuine safety risks.

Quality and Safety Considerations

When compounded semaglutide comes from a reputable, FDA-registered pharmacy with a valid prescription, the safety profile is generally considered reasonable — though not equivalent to FDA-approved Wegovy.

Documented concerns include:

• Incorrect dosing: Self-drawing doses from a vial introduces more room for error than a pre-filled pen
• Sterility risks: Improperly compounded injectables can cause serious infections
• Salt form controversy: The FDA has stated that semaglutide sodium and acetate salts are not the same as the active ingredient in approved products, raising questions about bioequivalence
• Additive interactions: The safety of adding B12 or other compounds to semaglutide is not established in clinical trials

The FDA has received reports of adverse events associated with compounded semaglutide, including nausea, vomiting, and dosing errors — some serious. This doesn’t mean compounded semaglutide is inherently dangerous, but it does mean the pharmacy source matters enormously.

The FDA Shortage Situation — and What’s Changed in 2025

Compounded semaglutide’s rise was directly tied to an FDA drug shortage. When Wegovy and Ozempic were placed on the FDA’s official drug shortage list, compounding pharmacies were legally permitted to produce copies of the drug under shortage exemptions.

That window is now narrowing:

• The FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in April 2025, triggering a phaseout period for compounded tirzepatide
• Semaglutide (Wegovy/Ozempic) has also seen improving supply, and the FDA has taken action against certain compounded semaglutide products
• As of early-to-mid 2025, many compounding pharmacies are navigating regulatory uncertainty and some have already stopped producing semaglutide compounds

The practical implication: the compounded semaglutide landscape is changing fast. If you’re currently on a compounded product, this is a good time to talk to your doctor about your options going forward — whether that means transitioning to brand name, exploring insurance coverage, or considering tirzepatide alternatives.

Who Should Consider Compounded vs. Brand Name?

There’s no universal right answer, but here are some honest guidelines:

Compounded semaglutide may make sense if:

• You don’t have insurance coverage for Wegovy and can’t afford $1,300+/month
• You have a valid prescription from a licensed provider
• You’re sourcing from a verified, FDA-registered 503B outsourcing facility
• Your prescribing doctor is monitoring your treatment

Brand-name Wegovy may be the better choice if:

• You have insurance that covers it or qualify for manufacturer savings programs
• You prefer the simplicity and standardization of a pre-filled pen
• You want the full backing of FDA approval and post-market safety data
• You’re concerned about the regulatory uncertainty around compounding

What to Look for in a Reputable Compounding Pharmacy

If you do go the compounded route, don’t just shop for the lowest price. Here’s what to verify:

1. FDA registration: Look for 503B outsourcing facility status — these are inspected by the FDA and held to higher standards than 503A pharmacies
2. State licensure: Verify the pharmacy is licensed in your state
3. Requires a valid prescription: Walk away from any source that doesn’t require a prescription from a licensed provider
4. Certificate of Analysis (COA): Reputable pharmacies can provide third-party lab testing results confirming purity and potency
5. Transparent ingredients: Know exactly what’s in your compound — including any additives like B12
6. No “research chemical” language: If a site sells semaglutide as a “research peptide” or “not for human use,” it’s not a legitimate pharmacy
7. Real prescriber involvement: Your prescriber should be managing your dosing, not an algorithm

Questions to Ask Your Doctor

Before deciding between compounded and brand name, bring these questions to your next appointment:

• “Do I qualify for Wegovy coverage under my insurance plan?”
• “Are there manufacturer savings programs I’m eligible for?”
• “If I use a compounded version, which pharmacy do you recommend — and why?”
• “What’s the dosing schedule, and how do I draw and inject from a vial safely?”
• “How will we monitor my progress and side effects?”
• “Given the FDA shortage status changes, what should I plan for long-term?”
• “Is tirzepatide (Zepbound/Mounjaro) a better fit for me given current availability?”

The Bottom Line

Compounded semaglutide has genuinely helped thousands of people access GLP-1 treatment who couldn’t otherwise afford it. The cost savings are real, and when sourced from a reputable, FDA-registered pharmacy with a valid prescription and proper medical oversight, the risk profile is manageable.

That said, it’s not the same as brand-name Wegovy. The regulatory landscape is shifting, quality varies significantly by source, and the window for legal compounding may be tightening as drug shortages resolve.

The smart move: don’t go it alone. Work with a licensed healthcare provider, ask the hard questions about your pharmacy’s credentials, and make sure whoever is prescribing your medication is actually monitoring your progress — not just writing scripts.

GLP-1 medications are genuinely powerful tools for weight loss. Whether you end up on compounded or brand-name semaglutide, the goal is the same: sustainable results with your health protected.